GlassScriptPhysician profile
Maja Marinkovic
NPI 1053469767
$5,136.40
in general payments reported to CMS, 2019-2025
25 companies · $969 in 2025
The $969 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $1,440 · 2021: $73.92 · 2023: $425 · 2024: $1,066 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $1,390.73 | 2019-2020 | |
| Novo Nordisk INC | $540.80 | 2019-2025 | Sogroya, Wegovy |
| Dexcom, INC. | $467.09 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $367.55 | 2019-2025 | |
| Tolmar, INC. | $345.90 | 2024-2025 | Fensolvi |
| Ipsen Biopharmaceuticals, INC | $327.04 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $258.46 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $242.31 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Azurity Pharmaceuticals, INC. | $197.40 | 2023-2025 | Triptodur, Triptodur |
| Ascendis Pharma Endocrinology INC | $176.59 | 2024-2025 | Skytrofa |
| Companion Medical, INC. | $145.39 | 2019 | |
| Eton Pharmaceuticals, INC. | $123.32 | 2024-2025 | Alkindi, Khindivi, Increlex |
| Insulet Corporation | $99.96 | 2019-2025 | Omnipod |
| Beta Bionics, INC. | $91.38 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Neurocrine Biosciences, INC. | $64.77 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $61.88 | 2025 | |
| Lilly USA, LLC | $54.94 | 2019-2025 | Mounjaro |
| Medtronic, INC. | $31.95 | 2023 | Minimed 780g |
| Kyowa Kirin, INC. | $26.64 | 2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $24.20 | 2025 | |
| Sequel Med Tech, LLC | $23.01 | 2025 | Twiist |
| Glaxosmithkline, LLC. | $22.14 | 2025 | Trelegy Ellipta |
| Alexion Pharmaceuticals, INC. | $20.30 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.04 | 2019 | |
| Soleno Therapeutics, INC. | $14.61 | 2025 | Vykat Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maja Marinkovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.